Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28


nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Parikh V, Kutlu MG, Gould TJ.

Schizophr Res. 2016 Mar;171(1-3):1-15. doi: 10.1016/j.schres.2016.01.020. Epub 2016 Jan 21. Review.


Nicotine effects in adolescence and adulthood on cognition and α₄β₂-nicotinic receptors in the neonatal ventral hippocampal lesion rat model of schizophrenia.

Berg SA, Sentir AM, Bell RL, Engleman EA, Chambers RA.

Psychopharmacology (Berl). 2015 May;232(10):1681-92. doi: 10.1007/s00213-014-3800-2. Epub 2014 Nov 13.


Striatal cholinergic interneuron regulation and circuit effects.

Lim SA, Kang UJ, McGehee DS.

Front Synaptic Neurosci. 2014 Oct 21;6:22. doi: 10.3389/fnsyn.2014.00022. eCollection 2014. Review.


Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D'Souza DC.

Curr Pharm Des. 2014;20(31):5077-92. Review.


An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia.

Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE.

J Dual Diagn. 2013;9(1):87-93.


High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness.

Lewis AS, Picciotto MR.

Psychopharmacology (Berl). 2013 Oct;229(3):477-85. doi: 10.1007/s00213-013-3126-5. Epub 2013 Apr 28. Review.


Α4β2 and α7 nicotinic acetylcholine receptor binding predicts choice preference in two cost benefit decision-making tasks.

Mendez IA, Damborsky JC, Winzer-Serhan UH, Bizon JL, Setlow B.

Neuroscience. 2013 Jan 29;230:121-31. doi: 10.1016/j.neuroscience.2012.10.067. Epub 2012 Nov 14.


Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia.

D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, Pittman B, Ranganathan M, Cosgrove K, Staley J.

Am J Psychiatry. 2012 Mar;169(3):326-34. doi: 10.1176/appi.ajp.2011.11020189.


Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A.

Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.


Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

D'Souza MS, Markou A.

Neuropharmacology. 2012 Mar;62(3):1564-73. doi: 10.1016/j.neuropharm.2011.01.044. Epub 2011 Feb 1. Review.


Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus.

André JM, Leach PT, Gould TJ.

Neuropharmacology. 2011 Mar;60(4):617-25. doi: 10.1016/j.neuropharm.2010.12.004. Epub 2010 Dec 16.


Activation of presynaptic alpha7 nicotinic receptors evokes an excitatory response in hippocampal CA3 neurones in anaesthetized rats: an in vivo iontophoretic study.

Huang LT, Sherwood JL, Sun YJ, Lodge D, Wang Y.

Br J Pharmacol. 2010 Feb 1;159(3):554-65. doi: 10.1111/j.1476-5381.2009.00529.x. Epub 2010 Jan 26.


Role of the central cholinergic system in the therapeutics of schizophrenia.

Terry AV Jr.

Curr Neuropharmacol. 2008 Sep;6(3):286-92. doi: 10.2174/157015908785777247.


TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.

Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, Stachowiak EK, Stachowiak MK, Papke RL, Lippiello PM, Bencherif M.

Biochem Pharmacol. 2009 Oct 1;78(7):803-12. doi: 10.1016/j.bcp.2009.05.030. Epub 2009 May 29.


Chronic underactivity of medial frontal cortical beta2-containing nicotinic receptors increases clozapine-induced working memory impairment in female rats.

Levin ED, Perkins A, Brotherton T, Qazi M, Berez C, Montalvo-Ortiz J, Davis K, Williams P, Christopher NC.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):296-302. doi: 10.1016/j.pnpbp.2008.12.003. Epub 2008 Dec 24.


Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Brasić JR, Zhou Y, Musachio JL, Hilton J, Fan H, Crabb A, Endres CJ, Reinhardt MJ, Dogan AS, Alexander M, Rousset O, Maris MA, Galecki J, Nandi A, Wong DF.

Synapse. 2009 Apr;63(4):339-58. doi: 10.1002/syn.20611.


Predictors of early abstinence in smokers with schizophrenia.

Culhane MA, Schoenfeld DA, Barr RS, Cather C, Deckersbach T, Freudenreich O, Goff DC, Rigotti NA, Evins AE.

J Clin Psychiatry. 2008 Nov;69(11):1743-50. Epub 2008 Oct 21.


The effects of galantamine on psychopathology in chronic stable schizophrenia.

Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP, Buchanan RW.

Clin Neuropharmacol. 2009 Mar-Apr;32(2):69-74. doi: 10.1097/WNF.0B013E31816F2795.


Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia.

Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE.

Psychopharmacology (Berl). 2008 Jul;199(1):89-98. doi: 10.1007/s00213-008-1133-8. Epub 2008 Jun 12.

Supplemental Content

Support Center